about
Night Activity Reduction is a Signature Physiological Biomarker for Duchenne Muscular Dystrophy Dogs.Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy.Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophiesForelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients.Proof of concept of the ability of the kinect to quantify upper extremity function in dystrophinopathySkeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.Pseudoexon activation increases phenotype severity in a Becker muscular dystrophy patient.Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function.Cardiac considerations in the operative management of the patient with Duchenne or Becker muscular dystrophy.Treatment of dystrophin cardiomyopathies.Angiogenesis as a novel therapeutic strategy for Duchenne muscular dystrophy through decreased ischemia and increased satellite cells.Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions.Clinical Follow-Up for Duchenne Muscular Dystrophy Newborn Screening: A Proposal.Inflammation and cardiac dysfunction during sepsis, muscular dystrophy, and myocarditis.A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides.Treating muscular dystrophy by stimulating intrinsic repair.The relationship between quality of life and health-related quality of life in young males with Duchenne muscular dystrophy.Dystrophic Cardiomyopathy: Complex Pathobiological Processes to Generate Clinical Phenotype.Skipping Multiple Exons to Treat DMD-Promises and Challenges.Parental Reflections on the Diagnostic Process for Duchenne Muscular Dystrophy: A Qualitative Study.Becker and Duchenne muscular dystrophy: a two-way information process for therapies
P2860
Q28596730-B9F39B49-CF46-4692-BBF5-88B7E56CE03EQ33678893-9FB50C11-F3C3-4A09-9173-1A7AADE89504Q33991470-91359381-97CE-44C1-BA26-85756E86D28AQ34041966-70EA2CEF-2CD7-4037-A5FF-D37B7D68E977Q34630606-3E8211CD-70EA-43CC-A4A2-C8ED87F9602BQ34995170-683FFFF2-4C0B-4C5A-A5D7-76F6AD3A3B46Q35907748-9D6CD5EB-1D51-40BF-BC1B-2FC5DCCA6AC7Q36422465-F26528E6-8AA9-4BAA-826D-6DCA4675647AQ37497985-A156A140-6074-4239-ADF7-6CE76F9DA66BQ38122702-366C1DAE-151D-45DB-A17F-67108F5E0F8FQ38178061-7366FBF0-3417-482D-8F84-655C37DE30B1Q38193799-5D9C8D06-0A58-479D-A5C3-5CCB9411E085Q38267714-370F7AEA-2A7A-4ACE-AAB2-C2378B294E91Q38832537-81B655A9-B051-4D19-948B-4934ADC14E2FQ38940783-B5CE94E5-98B9-4DCD-8194-B8ADB51593D0Q41877911-C6114475-68EC-416A-944C-078FAB05E6FEQ46403550-2F7F73BC-199D-42F1-B258-067A3EFF83ACQ47550375-8B7212E4-D3A1-4E17-A1A7-39F38FBF1340Q49428049-344A1CD5-392E-4731-AE02-16BF58FD7E3BQ52429827-F863CBDA-4B68-42D5-B0E3-39A2AA3BBF23Q54913104-D975CCD4-DB94-4B96-B000-8120FF6DE7D5Q57389868-46A921BA-E2CF-4B70-9F7D-0DC66E988DBE
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Update on the treatment of Duchenne muscular dystrophy.
@en
type
label
Update on the treatment of Duchenne muscular dystrophy.
@en
prefLabel
Update on the treatment of Duchenne muscular dystrophy.
@en
P2093
P2860
P1476
Update on the treatment of Duchenne muscular dystrophy.
@en
P2093
Jerry R Mendell
Louise R Rodino-Klapac
Zarife Sahenk
P2860
P2888
P356
10.1007/S11910-012-0332-1
P577
2013-03-01T00:00:00Z
P5875
P6179
1022600364